ClinicalTrials.Veeva

Menu

Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy

A

Aarhus University Hospital

Status

Unknown

Conditions

Polyneuropathies
Diabetes Complications
Insulin-like Growth Factor II
Insulin-like Growth Factor I
Nerve Growth Factors

Study type

Observational

Funder types

Other

Identifiers

NCT01718015
1-10-72-470-12.
1-16-02-272-12 (Other Identifier)

Details and patient eligibility

About

Background: The pathogenetic factors underlying development of diabetic polyneuropathy (DP) remain unclear. Reduced neurotrophic stimulation has been proposed as a possible mechanism. The neurotrophic factors IGF I and II, sCD-163, NGF, VEGF and BDNF are essential for development and regeneration of the nervous system. In earlier studies reduced concentrations of IGF-I and II in blood and reduced concentrations of NGF and BDNF in muscle and skin biopsies have been found in patients with DP.

Purpose: Our purpose is to determine the concentration and biological activity of Insulin-like Growth Factor I and II (IGF-I and II), soluble Cluster of Differentiation 163 (sCD-163), Nerve Growth Factor (NGF), Vascular Endothelial Growth Factor (VEGF) and Brain-derived Neurotropic Factor (BDNF) in cerebrospinal fluid and in blood in patients with diabetes and/or nerve disease (especially diabetic polyneuropathy) as well as in healthy control subjects. We will furthermore relate the findings to peripheral nerve function. In addition the composition of the cerebrospinal fluid will be analyzed using mass spectrometry.

Hypothesis: We hypothesize that DP develops due to reduced concentration and biological activity of neurotrophic factors. We expect the concentration of IGF-I and II, VEGF, NGF and BDNF to be reduced in cerebrospinal fluid in patients with DP compared to diabetic patients without damage to the nervous system and healthy control subjects.

Methods: Study subjects consists of patients from Department of Neurology and Department of Department of Clinical Medicine (Endocrinology and Diabetes) Aarhus University Hospital, Denmark, who are having a lumbar puncture performed.

Enrollment

70 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients with diabetic polyneuropathy
  • Patients with diabetes without peripheral nerve disorder
  • Patients with polyneuropathies not due to diabetes
  • Patients not suffering from diabetes or nerve disease (control subjects)
  • Patients with unspecified nerve disease

Exclusion criteria

  • Other causes to the development of polyneuropathy in patients with diabetic polyneuropathy
  • Cerebral infections

Trial design

70 participants in 5 patient groups

Patients with diabetic polyneuropathy
Patients with diabetes without peripheral nerve disorder
Patients with polyneuropathies not due to diabetes
Patients not suffering from diabetes or nerve disease
Description:
Control subjects
Patients with unspecified nerve disease

Trial contacts and locations

1

Loading...

Central trial contact

Mia Jørgensen, medical research year student

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems